key: cord-1052177-ihqwrbwp
authors: Hsin, Michael; Cypel, Marcelo
title: Commentary: Gift of life in the time of COVID-19.
date: 2020-11-28
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2020.11.081
sha: f76bb3ee5244a6a60f11bc0ef3b6b2c6abceee17
doc_id: 1052177
cord_uid: ihqwrbwp

nan

The COVID-19 pandemic has placed unprecedented pressure on health care systems, and drained hospital resources such as ICU beds and ECMO pumps. Reports from USA and France show that lung transplantation (LTx) activity is severely reduced. [1, 2] Extreme pressure on intensivists, the responsible use of limited hospital resources, and the risks of COVID infection to health care worker (HCW) and recipients, represent challenges which need to be balanced against waitlist mortality.

In this issue, Wu et al [3] reported a retrospective study to evaluate the feasibility and safety of performing LTx during the COVID-19 pandemic using data from the China Lung Transplant Registry between 23 rd January to 23 rd March 2020, and benchmarked against a cohort from a similar period in 2019. They implemented special measures that addressed the safety of organ donation, organ transport, selection of recipients, and the clustering of LTx surgery in designated centers, to minimize the risk of COVID exposure to recipients and HCWs.

Their 2020 cohort consisted of 28 cases, 5 of which were COVID ARDS. In 2020, 25% of recipients required preoperative ventilation and/ or ECMO. The 30-and 90-day mortality were J o u r n a l P r e -p r o o f 10.7% and 14.3% respectively (20% and 28.3% for the 2019 cohort). The PGD 2/3 rates were similar, although the preoperative gas exchange was worse in the 2020 cohort. ICU stay and infection episodes were better in 2020. No infection was reported in HCW involved in donation or transplantation. While these results are encouraging, there are limitations. These LTx occurred during the decline of the pandemic in China, whereas in the west the pandemic is not waning.

Relocating LTx surgery to designated centers is not readily replicable elsewhere.

LTx for COVID-ARDS is controversial, but experience is accumulating in support of this therapy for very selected patients [4] [5] [6] . This series from China included five COVID-ARDS patients who underwent LTx, with two deaths. One corresponded to the reported case who had uncontrolled intraoperative bleeding, [5] and the other case died from severe sepsis. Especially with a current very high incidence of COVID-19 in parts of the world such as Europe and USA, even a small selected subset of severely affected patients may represent a very large number.

With the predicted significant increase in demand, more than ever, strategies to optimize donor organ utilization such as extended criteria donor, donation after cardiac death, and ex vivo lung perfusion become critical to avoid high wait list mortality.

In the Chinese series, 9 more patients with COVID-ARDS were referred for LTx but were not accepted-six died, but three were successfully weaned off ECMO and ventilator. ARDS patients with complete absence of organ function from influenza or bacterial pneumonia can recover after weeks on ECMO [7, 8] and recovery rate of patients with COVID ARDS on ECMO maybe similar to patients with ARDS from other causes. [9] It is prudent to allow a period of at least 4-6 weeks to allow for lung recovery before considering LTx. [7] More information regarding the clinical outcomes of post COVID-ARDS subset of patients, both those who were transplanted and the survivors without LTx, would be of very high interest.

J o u r n a l P r e -p r o o f

Early Impact of COVID-19 on Solid Organ Transplantation in the United States

Groupe Transplantation Pulmonaire de la Société de Pneumologie de Langue Française SPLF. Impact of the Covid-19 pandemic and lung transplantation program in France

Lung transplantation during the outbreak of Coronavirus disease 2019 (COVID-19) in China

Lung Transplantation for Elderly Patients With End-Stage COVID-19 Pneumonia

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCRpositive patient

When to consider lung transplantation for COVID-19

Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS